Hi Harry,

That's not what I said (sorry). I just quoted the AFFIRM Tysabri monotherapy trial results, which found a relative risk reduction of disability progression of about 43% but an absolute risk reduction of 12% (29% placebo vs. 17% on Tysabri, or a difference of 12%).

By contrast, the phase III Avonex trial found a relative risk reduction of disability progression of about 37%, but an absolute risk reduction of 13% (35% placebo vs. 22% Avonex).

So in a two year period, the number of people who would not suffer disability progression as a result of Tysabri or Avonex, is about the same, based on these trial results.

Mark